Unknown EARLY_PHASE1 INTERVENTIONAL 1-arm NCT04156178

CD20-CD19 Compound CAR (cCAR) T Cells for Patients With Relapsed /Refractory B Cell Malignancies

Phase I, Interventional, Single Arm, Open Label, Treatment Study to Evaluate the Safety and Tolerability of CD20-CD19 cCAR in Patients With Relapsed and/or Refractory B Cell Malignancies

Sponsor: Chengdu Military General Hospital

Conditions B Cell Leukemia B Cell Lymphoma

Interventions CD20-CD19 cCAR T cells

Updated 6 times since 2019 Last updated: Nov 8, 2019 Started: Aug 1, 2018 Primary completion: Sep 30, 2020 Completion: Sep 30, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04156178, this EARLY_PHASE1 trial focuses on B Cell Leukemia and B Cell Lymphoma and remains ongoing. Sponsored by Chengdu Military General Hospital, it has been updated 6 times since 2018, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Unknown EARLY_PHASE1
Jul 2024 — Sep 2024 [monthly]

Unknown EARLY_PHASE1

Status: Unknown Status → Unknown
Oct 2021 — Jul 2024 [monthly]

Unknown Status EARLY_PHASE1
Feb 2021 — Oct 2021 [monthly]

Unknown Status EARLY_PHASE1

Status: Recruiting → Unknown Status
Jan 2021 — Feb 2021 [monthly]

Recruiting EARLY_PHASE1

▶ Show 1 earlier version

Dec 2019 — Jan 2021 [monthly]

Recruiting EARLY_PHASE1

First recorded

Aug 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Chengdu Military General Hospital
Peking University Shenzhen Hospital
iCAR Bio Therapeutics Ltd.
iCell Gene Therapeutics

Data source: iCell Gene Therapeutics

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Chengdu, China
• Shanghai, China